Hjem
Dorota Katarzyna Pazdyk Goplens bilde

Dorota Katarzyna Pazdyk Goplen

Sekretær
  • E-postdorota.goplen@uib.no
  • Besøksadresse
    Christies gate 12
    5015 Bergen
  • Postadresse
    Postboks 7807
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2023). Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. PLOS ONE. 15 sider.
  • Vis forfatter(e) (2023). Outcomes in Norwegian Cohort with Malignant Orbital Tumours. Acta Ophthalmologica.
  • Vis forfatter(e) (2023). Feasibility of deep learning-based tumor segmentation for target delineation and response assessment in grade-4 glioma using multi-parametric MRI. Neuro-Oncology Advances (NOA).
  • Vis forfatter(e) (2022). Brain Tumor Segmentation from Multiparametric MRI Using a Multi-encoder U-Net Architecture. Lecture Notes in Computer Science (LNCS).
  • Vis forfatter(e) (2022). Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway. Frontiers in Cell and Developmental Biology. 1-23.
  • Vis forfatter(e) (2021). Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST). ESMO Open.
  • Vis forfatter(e) (2020). Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study. Immunity,Inflammation and Disease. 342-359.
  • Vis forfatter(e) (2019). Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. British Journal of Cancer. 545-555.
  • Vis forfatter(e) (2018). Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors—A Scandinavian Sarcoma Group study (SSG XX). European Journal of Cancer. 78-85.
  • Vis forfatter(e) (2016). Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats. Journal of Neuro-Oncology.
  • Vis forfatter(e) (2016). Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models. BMC Cancer. 12 sider.
  • Vis forfatter(e) (2010). alpha B-Crystallin Is Elevated in Highly Infiltrative Apoptosis-Resistant Glioblastoma Cells. American Journal of Pathology. 1618-1628.
  • Vis forfatter(e) (2010). Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium. Neurosurgery. 933-947.
  • Vis forfatter(e) (2010). Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment. Gene Therapy. 202-216.
  • Vis forfatter(e) (2008). Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma. Clinical Cancer Research. 1571-1580.
  • Vis forfatter(e) (2006). Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Research. 9895-9902.
  • Vis forfatter(e) (2006). Expression studies in gliomas and glial cells do not support a tumor suppressor role for LGI1. Neuro-Oncology. 96-108.
Vitenskapelig foredrag
  • Vis forfatter(e) (2022). Phase I trial of Sulfasalazine combined with Stereotactic Radiosurgery for recurrent Glioblastoma: Study protocol for NCT04205357.
  • Vis forfatter(e) (2022). Phase I trial of Sulfasalazine combined with Stereotactic Radiosurgery for recurrent Glioblastoma: Study protocol for NCT04205357.
  • Vis forfatter(e) (2022). Phase I trial of Sulfasalazine combined with Stereotactic Radiosurgery for recurrent Glioblastoma: Study protocol for NCT04205357.
  • Vis forfatter(e) (2022). Phase I trial of Sulfasalazine combined with Stereotactic Radiosurgery for recurrent Glioblastoma: Study protocol for NCT04205357.
  • Vis forfatter(e) (2022). Phase I trial of Sulfasalazine combined with Stereotactic Radiosurgery for recurrent Glioblastoma: Study protocol for NCT04205357.
Brev til redaktøren
  • Vis forfatter(e) (2023). Exploiting Deep Learning to Enhance Tumour-conformed Delineation and Reduced Isotropic Margin in Radiotherapy: Updated ESTRO-EANO Guidelines. Clinical Oncology. e636-e638.
Doktorgradsavhandling
  • Vis forfatter(e) (2010). Invasiveness, biological and therapeutic aspects in humanglioblastoma.
Sammendrag/abstract
  • Vis forfatter(e) (2013). COMBINED ANTI-ANGIOGENIC AND ANTI-INVASIVE TREATMENT OF ORTHOTOPICALLY ENGRAFTED HUMAN GBM XENOGRAFTS. Neuro-Oncology. 43-43.
  • Vis forfatter(e) (2005). Bacitracin inhibits glioma cell migration and invasion in vitro. Neuro-Oncology. 357-357.
Fagartikkel
  • Vis forfatter(e) (2023). Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH- mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden. BMJ Open.

Se fullstendig oversikt over publikasjoner i CRIStin.